Hexaminolevulinate Hydrochloride Patent Expiration
Hexaminolevulinate Hydrochloride is Used for detection and diagnosis of bladder cancer using photodynamic cystoscopy. It was first introduced by Photocure Asa
Hexaminolevulinate Hydrochloride Patents
Given below is the list of patents protecting Hexaminolevulinate Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cysview Kit | US11235168 | Method of photodynamic therapy (PDT) for bladder cancer | Jan 04, 2038 | Photocure Asa |
| Cysview Kit | US10556010 | Neoadjuvant therapy for bladder cancer | Dec 19, 2036 | Photocure Asa |
| Cysview Kit | US11311620 | Neoadjuvant therapy for bladder cancer | Dec 19, 2036 | Photocure Asa |
| Cysview Kit | US7348361 | Solution for diagnosing or treating tissue pathologies |
Apr 22, 2019
(Expired) | Photocure Asa |
| Cysview Kit | US7530461 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Jan 11, 2017
(Expired) | Photocure Asa |
| Cysview Kit | US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Mar 08, 2016
(Expired) | Photocure Asa |
| Cysview Kit | US7247655 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Mar 08, 2016
(Expired) | Photocure Asa |
Hexaminolevulinate Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Hexaminolevulinate Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE2 |